Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1104653

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, whether they will update their guidance given to companies that supply (1) prescription only, (2) pharmacy, and (3) general sales list, medicines if Article 50 is extended.
	tabling member printed	Baroness Jolly
	uin	HL14778
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14777 HL14779 HL14780 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4203 label Biography information for Baroness Jolly

1104652

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, whether they have made any further preparations on stockpiling (1) pharmacy, and (2) general sales list, medicines in the event that Article 50 is extended.
	tabling member printed	Baroness Jolly
	uin	HL14777
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available online at GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes. Our plans cover all medicines and medical products, including general sales list medicines.</p><p> </p><p>The Department will continue to work on its ‘no deal’ plans, and we are writing in similar terms to all other organisations in the health and care system to ask them to continue and not to wind down their contingency plans at this stage. The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL14778 HL14779 HL14780 question first answered 02/04/2019 15:04:35 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4203 label Biography information for Baroness Jolly

1141916

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Records: Data Protection
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, whether, in referring to NHS organisations, national NHS organisations, pertinent departments and arms-length bodies are required not to enter into “exclusive arrangements for raw data held by them”.
	tabling member printed	Lord Freyberg
	uin	HL17460
	answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17458 HL17459 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2593 label Biography information for Lord Freyberg

1141915

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Records: Data Protection
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, which organisation or body will hold to account the boards of NHS organisations in ensuring that "any arrangements entered into by their organisation are fair, including recognising and safeguarding the value of the data that is shared and the resources which are generated as a result of the arrangement”.
	tabling member printed	Lord Freyberg
	uin	HL17459
	answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17458 HL17460 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2593 label Biography information for Lord Freyberg

1141914

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Records: Data Protection
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, in respect of its guidance Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation, published on 15 July, what is meant by "fair terms" for (1) NHS organisations, and (2) the NHS as a whole.
	tabling member printed	Lord Freyberg
	uin	HL17458
	answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>As set out in the recently published guidance <em>Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation,</em> the Centre of Expertise will offer support to those National Health Service organisations seeking to understand whether proposed data arrangements meet the requirements set out in the five guiding principles. The Centre of Expertise will sit in NHSX. The requirement that terms are agreed which are fair to both an NHS organisation and the wider NHS, is included to ensure, for example, that local NHS trusts consider arrangements which can provide benefits to the whole NHS, not just to an individual trust. This may include a NHS trust providing access to anonymised healthcare data for development of a healthcare product in return for access at a reduced cost to that product for the whole NHS, not just that particular trust. Fair terms should ensure that benefits returned to NHS organisations and the NHS as a whole are commensurate with the outputs that are generated by the data partner. The principles are intended to apply to all NHS organisations at the primary, secondary and tertiary care levels, including national NHS organisations. However, we will consider the inclusion of arm’s length bodies as part of the next phase of work in developing a full policy framework.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17459 HL17460 question first answered 07/08/2019 11:38:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2593 label Biography information for Lord Freyberg

1156333

	registered interest
	date	24/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Negligence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, in each of the last three years, (1) what was the total cost of clinical negligence cases to the NHS, (2) how many cases were resolved prior to going to court, (3) how many cases went to court; and (4) what was the percentage of those cases which were won by the NHS.
	tabling member printed	Lord Storey
	uin	HL416
	answer	answer is ministerial correction date of answer 30/10/2019 answer text <p>NHS Resolution handles clinical negligence claims on behalf of National Health Service organisations and independent sector providers of NHS care in England.</p><p>NHS Resolution has provided the following information:</p><p>The total cost of clinical negligence cases to the NHS.</p><table><tbody><tr><td><p>2016/17</p></td><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>£1,707.2 million</p></td><td><p>£2,275.5 million</p></td><td><p>£2,359.9 million</p></td></tr></tbody></table><p> </p><p>The number of cases resolved prior to going to court.</p><table><tbody><tr><td><p>2016/17</p></td><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>10,996</p></td><td><p>11,417</p></td><td><p>11,255</p></td></tr></tbody></table><p> </p><p> </p><p>The number of cases that went to court.</p><table><tbody><tr><td><p>2016/17</p></td><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>128</p></td><td><p>72</p></td><td><p>53</p></td></tr></tbody></table><p> </p><p> </p><p>The percentage of those cases which were won by the NHS.</p><table><tbody><tr><td><p>2016/17</p></td><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>56%</p></td><td><p>65%</p></td><td><p>57%</p></td></tr></tbody></table><p> </p><p>Note:</p><p>The above figures are in relation to the NHS in England only (Clinical Negligence Scheme for Trusts and other relevant schemes).</p><p>The figures provided do not include claims brought against general practice.</p> answering member printed Baroness Blackwood of North Oxford question first answered 30/10/2019 14:38:19 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4238 label Biography information for Lord Storey

1149776

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bevacizumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, if Avastin is approved for safe use, whether it could be privately purchased for use by a patient being treated on the NHS.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL69
	answer	answer is ministerial correction date of answer 28/10/2019 answer text <p>For patients receiving private and National Health Service care for the same condition, NHS and private treatment can be supervised by one healthcare team. However, patients cannot choose to mix different parts of the same treatment between NHS and private care.</p><p>For example, a patient cannot have a cataract operation on the NHS and pay privately for special lens implants that are normally only available as part of private care.</p><p>Instead, a patient either has both the operation on the NHS and standard NHS lens implants or pay for both the operation and implants privately.</p> answering member printed Baroness Blackwood of North Oxford question first answered 28/10/2019 12:58:25 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1167548

	registered interest
	date	30/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heroin: Rehabilitation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 28 October (HL Deb, col 772), what is the level of provision in different regions of England of heroin-assisted treatment involving addicts injecting safely.
	tabling member printed	Lord Rennard
	uin	HL556
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>Information on the level of provision of heroin assisted treatment is not centrally collected.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/11/2019 13:09:20 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1137092

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 3 July (HL Deb, col 1435), what assessment they have made of the finding of the House of Commons Health Committee in its report NHS Charges (HC815–1), published on 18 July 2006, that the list of exemptions for prescription charges was “inconsistent and anomalous”; and what plans they have, in any future meetings with Asthma UK, to discuss the current list of exemptions for prescription charges in regard to those who have asthma.
	tabling member printed	Lord Rennard
	uin	HL16956
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Department has made no formal assessment of the finding of the House of Commons Health Committee in its report NHS Charges (HC815–1), published on 18 July 2006, that the list of exemptions for prescription charges was “inconsistent and anomalous”. The Department has no current plans to review the existing National Health Service prescription charging exemption arrangements.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 11:04:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard

1167547

	registered interest
	date	30/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Methadone
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 28 October (HL Deb, col 772), why data on the costs of the supply of methadone are not collected centrally; and what data are available on the number of patients using methadone in different regions of England.
	tabling member printed	Lord Rennard
	uin	HL555
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>The Government does not collect detailed data like the costs of supplying specific drugs, such as methadone.</p><p>Public Health England collects data from the National Drug Treatment Monitoring System on the number of people in treatment for opiates who are receiving a pharmacological intervention. Most of these people received prescriptions as part of opiate substitution therapy, for which methadone is the most commonly prescribed medication.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/11/2019 13:09:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2484 label Biography information for Lord Rennard